Allergen-specific Immunoglobulin E against house dust mite (HDM-specific IgE)

Allergen-specific Immunoglobulin E (IgE) against house dust mite (HDM) is a specialized antibody that mediates Type I hypersensitivity in sensitized individuals (National Institutes of Health [NIH], 2023). These antibodies recognize specific proteins from HDM species, such as Dermatophagoides pteronyssinus and D. farinae, which are common indoor triggers for respiratory allergies (World Allergy Organization [WAO], 2021). When HDM-specific IgE binds to the high-affinity receptor FcεRI on mast cells and basophils, it primes these cells for activation; subsequent exposure to HDM allergens causes IgE cross-linking and the rapid release of inflammatory mediators like histamine (PubMed, 2022). This cascade is central to the pathogenesis of allergic asthma, allergic rhinitis, and atopic dermatitis (Journal of Allergy and Clinical Immunology [JACI], 2020). Therapeutic interventions, such as the monoclonal antibody Omalizumab, target the Fc region of circulating IgE to prevent its binding to receptors, thereby dampening the allergic response (DrugBank, 2024).

Other names

House dust mite-specific IgEHDM-sIgEAnti-HDM IgEDermatophagoides-specific IgEIgE against house dust mite

Anti-IgE therapies, such as Omalizumab, function by binding to the Cε3 domain of free serum IgE, which is the same site required for binding to the high-affinity FcεRI receptor (NCBI, 2023). This sequestration prevents IgE from sensitizing mast cells and basophils, effectively blocking the allergic cascade at its inception (PubMed, 2022). Furthermore, the reduction in free IgE levels leads to a secondary downregulation of FcεRI expression on the surface of effector cells, further decreasing their sensitivity to allergens (StatPearls, 2023).